{"ticker": {"uuid": "3ed64fee-f30f-4507-872b-90e665ba6381", "symbol": "TCRX", "name": "Tscan Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates", "summary": "TScan Therapeutics, Inc. (TCRX) announced a Q1 loss, missing revenue estimates. This indicates a challenging start to the fiscal year for the company, with financial performance not meeting analyst expectations.", "url": "https://www.msn.com/en-us/news/other/tscan-therapeutics-inc-tcrx-reports-q1-loss-lags-revenue-estimates/ar-AA22wkC3?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-17T17:39:14", "published_display": "17 Jul 2026 17:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "TScan Therapeutics (TCRX) Q4 2025 earnings summary", "summary": "TScan Therapeutics (TCRX) reported its Q4 2025 earnings, highlighting positive updated data from the ALLOHA Phase 1 heme trial and significant progress in its clinical pipeline, including FDA clearance for new INDs and the launch of a pivotal trial for TSC-101. Financially, the c", "url": "https://quartr.com/events/tscan-therapeutics-tcrx-q4-2025_Fet81OVH", "source_name": "Quartr", "published_at": "2026-07-10T12:10:27", "published_display": "10 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics (TCRX) Status Update Summary", "summary": "TScan Therapeutics (TCRX) provided a status update on its hematologic malignancy program, highlighting positive results from the Phase 1 ALLOHA trial for TSC100 and TSC101, which showed significant relapse reduction and improved event-free survival. The FDA granted RMAT designati", "url": "https://quartr.com/events/tscan-therapeutics-inc-tcrx-status-update_Fet8Top0", "source_name": "Quartr", "published_at": "2026-07-08T11:11:49", "published_display": "08 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics (TCRX) Stock Analysis Report | Financials & Insights", "summary": "This report provides a detailed financial analysis of TScan Therapeutics (TCRX), a clinical-stage biotechnology company focused on developing TCR-T therapies for cancer. It covers general company information, stock performance metrics, Benzinga Edge rankings, financial health ind", "url": "https://es.benzinga.com/quote/TCRX/report", "source_name": "Benzinga Espa\u00f1a", "published_at": "2026-07-06T23:09:46", "published_display": "06 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of TScan Therapeutics, Inc. \u2013 NASDAQ:TCRX", "summary": "This article examines the enterprise value to EBITDA forward for TScan Therapeutics, Inc. (NASDAQ: TCRX). It primarily presents a snapshot of financial data and company information available on TradingView, covering market specifics and financial metrics. The focus is on the valu", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T11:09:18", "published_display": "04 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of TScan Therapeutics, Inc. \u2013 NASDAQ:TCRX", "summary": "This article provides financial information for TScan Therapeutics, Inc. (NASDAQ: TCRX), focusing on its enterprise value to EBIT forward. It indicates a period value and details regarding changes in this metric, accessible through TradingView's platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T19:10:24", "published_display": "01 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics at H.C. Wainwright: phase iii push gains pace", "summary": "TScan Therapeutics presented at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference, announcing the transition of its lead program, TSC-101, into a phase III study. The company highlighted encouraging phase I data showing 100% relapse-free survival in a treated subset ", "url": "https://www.investing.com/news/transcripts/tscan-therapeutics-at-hc-wainwright-phase-iii-push-gains-pace-93CH-4768449", "source_name": "Investing.com", "published_at": "2026-06-30T18:39:50", "published_display": "30 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), TScan Therapeutics (TCRX) and PACS Group Inc (PACS)", "summary": "The article highlights positive analyst sentiments in the Healthcare sector for Definium Therapeutics (DFTX), TScan Therapeutics (TCRX), and PACS Group Inc (PACS). Analysts from JonesTrading, Wedbush, and J.P. Morgan reiterated Buy ratings for the respective companies, citing sig", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PACS/pressreleases/2624972/analysts-offer-insights-on-healthcare-companies-definium-therapeutics-dftx-tscan-therapeutics-tcrx-and-pacs-group-inc-pacs/", "source_name": "The Globe and Mail", "published_at": "2026-06-28T10:11:58", "published_display": "28 Jun 2026 10:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of TScan Therapeutics, Inc. \u2013 NASDAQ:TCRX", "summary": "The article discusses the enterprise value to revenue forward for TScan Therapeutics, Inc. (NASDAQ: TCRX). It appears to be a financial data snippet from TradingView, indicating no specific value or change but rather the financial metric is available. The content primarily shows ", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T14:10:09", "published_display": "26 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of TScan Therapeutics, Inc. \u2013 BOATS:TCRX", "summary": "This article provides the \"Price to sales forward\" financial metric for TScan Therapeutics, Inc. (TCRX) on the Blue Ocean Alternative Trade System (BOATS). It is presented within the context of TradingView's financial data offerings for investors.", "url": "https://www.tradingview.com/symbols/BOATS-TCRX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T12:10:09", "published_display": "26 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics to speak at H.C. Wainwright cell therapy event June 30", "summary": "TScan Therapeutics (Nasdaq:TCRX), a clinical-stage biotechnology company, announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. The company will host a fireside chat at 11:30 a.m. ET, with a live webcast and 90-day replay ", "url": "https://www.stocktitan.net/news/TCRX/t-scan-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-vk5y8c56gnxe.html", "source_name": "Stock Titan", "published_at": "2026-06-24T11:14:33", "published_display": "24 Jun 2026 11:14", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference", "summary": "TScan Therapeutics, a clinical-stage biotechnology company, announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. The company will host a fireside chat on June 30, 2026, at 11:30 a.m. ET, discussing its T cell receptor (TCR)-engineered T c", "url": "https://www.globenewswire.com/news-release/2026/06/24/3316713/0/en/TScan-Therapeutics-to-Participate-in-the-H-C-Wainwright-4th-Annual-Cell-Therapy-Virtual-Conference.html", "source_name": "GlobeNewswire", "published_at": "2026-06-24T11:14:33", "published_display": "24 Jun 2026 11:14", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TCRX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for TScan Therapeutics, Inc. (TCRX) stock, outlining current price, historical performance, and analyst opinions for future price movements. It also includes key financial metrics such as EPS, revenue, market capitalization, and u", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-24T09:11:23", "published_display": "24 Jun 2026 09:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TCRX Reiterated by Needham -- Price Target Maintained at $6.00", "summary": "Needham analyst Gil Blum reiterated a \"Buy\" rating for TScan Therapeutics (TCRX) and maintained a price target of $6.00. The stock is considered undervalued by 48.2% based on GuruFocus's GF Value\u2122 of $1.68 compared to its current price of $0.87. Despite an average GF Score\u2122 of 50", "url": "https://www.gurufocus.com/news/8927545/tcrx-reiterated-by-needham-price-target-maintained-at-600?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-23T17:10:14", "published_display": "23 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TCRX Reiterated by Wedbush -- Price Target Maintained at $5.00", "summary": "Wedbush has reiterated an Outperform rating for TScan Therapeutics (TCRX), maintaining a price target of $5.00. Despite a current market price of $0.87, GuruFocus estimates the stock to be 48.2% undervalued with a GF Value\u2122 of $1.68. While analysts express confidence in the compa", "url": "https://www.gurufocus.com/news/8927568/tcrx-reiterated-by-wedbush-price-target-maintained-at-500?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-23T17:10:14", "published_display": "23 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA\u2122 Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation", "summary": "TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA\u2122 Phase 1 study for TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The study showed 11 of 14 patients achieved complete donor chimerism short", "url": "https://www.sahmcapital.com/news/content/tscan-therapeutics-announces-positive-initial-data-from-cohort-c-of-ongoing-alloha-phase-1-study-evaluating-tsc-101-in-patients-with-heme-malignancies-undergoing-allogeneic-hematopoietic-cell-transplantation-2026-06-22", "source_name": "Sahm", "published_at": "2026-06-23T16:39:37", "published_display": "23 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6", "summary": "Needham has reiterated its Buy rating on TScan Therapeutics (TCRX.US) and maintained its target price at $6. This indicates the firm's continued confidence in the company's financial prospects and valuation.", "url": "https://www.moomoo.com/news/post/71891944/needham-maintains-tscan-therapeutics-tcrxus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-06-23T11:09:03", "published_display": "23 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $7", "summary": "H.C. Wainwright has reiterated its Buy rating for TScan Therapeutics (TCRX.US) and maintained a target price of $7. This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/71891943/hc-wainwright-maintains-tscan-therapeutics-tcrxus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-23T11:09:03", "published_display": "23 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Tscan stock rating on trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOMnNDMHVsaTRZRERMampnWDRaeWw4c2VRR1JIT1BtV3VCRUppWmd1TUx5RlByb2dZSHhiMEg3N0pFaE52bEp4dUJCYmQtR0lOLWNvc0Z0RE9DLXM4TUM4MlBTRTY2ZGU5MUs2MXRGQjJWNVo2YW1pZlR0ZlhpcjRGTzVIZXJXUDVkeUJjSTNvRkh3ai0xZmtCVnV1V1Z2YVYtTXRmQUlFeVFiUVo4dGUxV0lnQWV3MmFM?oc=5", "source_name": "Investing.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics (TCRX) shows strong TSC-101 Phase 1 data, plans pivotal trial", "summary": "TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA\u2122 Phase 1 study for TSC-101, a TCR-T cell therapy for blood cancer patients post-allogeneic stem cell transplant. The data show 11 of 14 patients achieved complete donor chimerism, with 93% exhibiting d", "url": "https://www.stocktitan.net/sec-filings/TCRX/8-k-t-scan-therapeutics-inc-reports-material-event-e2f367ca1aaa.html", "source_name": "Stock Titan", "published_at": "2026-06-23T03:39:40", "published_display": "23 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan reports Phase 1 data for TSC-101 blood cancer trial", "summary": "TScan Therapeutics announced promising initial Phase 1 data for its TSC-101 treatment in blood cancer patients, with 11 out of 14 achieving complete donor chimerism. The company's shares traded down following the news, and TScan expects to enroll the first patient in its pivotal ", "url": "https://grafa.com/en/news/united-states/tscan-therapeutics-tcrx-phase-1-trial-chimerism-data-2026", "source_name": "grafa.com", "published_at": "2026-06-22T13:35:00", "published_display": "22 Jun 2026 13:35", "sentiment": "negative", "sentiment_pct": 39, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tscan-therapeutics-reports-positive-data-123125587.html", "source_name": "MT Newswires", "published_at": "2026-06-22T12:31:25+00:00", "published_display": "22 Jun 2026 12:31", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan reports trial data for blood cancer treatment TSC-101 By Investing.com", "summary": "TScan Therapeutics Inc. (NASDAQ:TCRX) released promising data from Cohort C of its ALLOHA Phase 1 study for TSC-101, a blood cancer treatment. The study showed 11 out of 14 treated patients achieved complete donor chimerism, and the infusions were generally well-tolerated. Despit", "url": "https://ng.investing.com/news/stock-market-news/tscan-reports-trial-data-for-blood-cancer-treatment-tsc101-93CH-2567285", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T11:40:15", "published_display": "22 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Tscan Therapeutics Inc For: 22 June By Investing.com", "summary": "This article announces that Tscan Therapeutics Inc. filed a Form 8K on June 22nd. The brief post from Investing.com includes general market data and related news but offers no specifics about the content of the Form 8K filing itself. The article also touches on various market ind", "url": "https://ca.investing.com/news/stock-market-news/form-8k-tscan-therapeutics-inc-for-22-june-93CH-4700450", "source_name": "Investing.com Canada", "published_at": "2026-06-22T11:40:15", "published_display": "22 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan says 11 of 14 patients hit complete donor chimerism after TSC-101", "summary": "TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA Phase 1 study for TSC-101, reporting that 11 out of 14 patients achieved complete donor chimerism within approximately three weeks of their first infusion. The company also confirmed a ~90% manufacturi", "url": "https://www.stocktitan.net/news/TCRX/t-scan-therapeutics-announces-positive-initial-data-from-cohort-c-of-oj3vilv79red.html", "source_name": "Stock Titan", "published_at": "2026-06-22T10:40:15", "published_display": "22 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of TScan Therapeutics, Inc. \u2013 NASDAQ:TCRX", "summary": "This article provides information about the number of shareholders of TScan Therapeutics, Inc. (NASDAQ: TCRX) through a TradingView interface. It presents data points for \"Period,\" \"Value,\" \"Change,\" and \"Change %\" without specifying the actual shareholder numbers or the periods ", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRX/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-20T05:40:23", "published_display": "20 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics Inc (TCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for TScan Therapeutics Inc (TCRX), focusing on its business segments, regional revenue, and profit contribution. It notes that relevant financial data for FY2025 has not yet been disclosed by the company. The only specific financial detai", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:37", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cellares-tscan-therapeutics-announce-agreement-131900798.html", "source_name": "Business Wire", "published_at": "2026-06-03T13:19:00+00:00", "published_display": "03 Jun 2026 13:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Automated cell therapy push: TScan and Cellares target post-transplant relapse", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQNEZKTFRXYmlpT3ZFdTBEZDJCejZndjJlODlHMjhONDV2RWd2M3UtX19DWGVfX1JBbWhERDM4T19lY3M1SnBWRHFIeGJSV3dialZRR1MxZkhudmt1NjZQQUpwOS1kNEQzRHNhUUN4XzZfQzZ1YllnYWJpMkZjTFJnTW1BemZHZ0E5Mk4wME90bDJzYkotY0c2TXJfcWRoYWtFS3U2aTJYWkRkR1JPV1BNSGhLMnRtRWhYV1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxObkxkdDZ3blhoZmVXYi1VdXJuQUJhN3hNSENQT08wbFQxZmMyUTlFUGFRUlVlS19wYUxISm56Z3R1cThhXzlsUVhsZGxMQU9KM3FGX0VoaTJoUHotc0paUF9DUTk1dG9RU3RoRF8yeWJFMmdhc3lSYVZoRDg1UGZ3UUY5MS1zWXZJOXh2Qzh0QXlkemV6QkFxTFdBQmh1cFRVdWQ4NWJSSQ?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxOa2RUWl9tanUwTmZuQVZMSUxyeTRuOWtMRjJwRkFNSWYxcWlXVnkteloxZERDTVphaXBrcGJuUkl6V0lHRzg0VENsb1RPWmdaenYwY2ZqelpwLU5aYUQ4N1c4Z1Q3eXRSOWtjazh5c25sSHZaRXRSTlZCdHNIV2pEOENrMmJlYll3algxX3lGMFQ0MkJlVFQ5YUFBMkN3enhwdEhwT2JRRlpEMlJhV0VCRW96LWlwczZkVy04b1dZTzhjNkVkcW9vN1NNbjNFSnFjN3ZwYmJFS2RZb1ZFUzc1eW1NYTF6VWhjZDVTYTlBSHJBYXVMM2c?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan lines up Phase 3 blood cancer study as patient data nears", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTXdHVkMzeENObFYzeWtDWFRGZEtGM1JZRVBXNlFkYnVFWjdjTVNVYzdQc3hnd1FqSVJ1dF9OOWp1LW1WRUJOZmRnbm5Jb3VtMllqV3lUTXFHbWNKeFE2MVFILU9tQjZBQk1HNGF2NF9ORVMtY0lfdG5zc2tlRVRqVDVCeG0yT0ZkTzRKcFpOblQ5N1dScDBkbnF0OWVmRWpnZG9ldGhWdkIwSXMzeG9zWDU2VzR6WGU0UVVXTFlrZU0?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tscan-therapeutics-announces-upcoming-presentation-203000315.html", "source_name": "GlobeNewswire", "published_at": "2026-04-27T20:30:00+00:00", "published_display": "27 Apr 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "LifeSci Capital Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQR0JzQUljdFQwbTRNSllqeFRhX0tDU1pHVXR5S28xSXFtTmdDNXNnNmZaOWEzWVEyZ3l1OTlTU1VCOGRtTGt0RE03U2hOaDlkQ0JRWFB1eXIzZ2YzYU83TExFZF9WVjhfOVdiTlFmWXdLV0NqbDJ2QU1tUXM1VGZRT0FndDlyclY1YlpHQmdpU21jV3VHVkludUhsMjdab0R0SEZzRVpsZi1rQl9iUEZzVlFsRlFNdGVuN3E4?oc=5", "source_name": "Moomoo", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQQ0hNYlg0bUM5bUlWVDB1NnRPVzFha0l6RTNVeHh1VFJtLTAyRGRUcTRHVEhydFVFRzNNaTVsajZTMENGYmJqcU5fWkQ1aHpCWTd4bC12SmJnQnRMdnIzQnFQX0pkOXcyN1k3eGxDdmNXTWhlQzV4Uk5WMFR1b09VOFlMZUg1ekhRRTI5TW1sZ1hXYjhPUnhTSy1nallxTDVQaVl1YnNJNnB0cG56?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics Announces Positive Phase I Meeting with FDA, Strategic Workforce Reduction, and Focus on Hematologic Malignancies | TCRX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxOcFU1QkRMTnFZWU96aTdvUjNuQWV4Q3hqU081NV9WV1Z4bGI4NDEtMzJLLXltN3RwVEJaWHU1RVdwbzRUM2VCTi1DdXdsSjRXUDM5Q3lha0Z0RVJkSS1UbnhqaVBRR2x5RHh5eTg0cHFlZVQzNW5ETDZXUFdud0xNbW5FaDBmRFc0QkdKblJONHJjLVozcHhBSzRtb1JxZndWZWlqWlZVa0JuS2JTYmUzbjU5YW1ZZlZUbEhTQ3ViZ1l1UTJEVG5WWFhhWmF0N24xd2lOdk5Yb3hFYXdaU3VIaWdMYlltS0JjWHhwMnNVRVJ0c0pEOW5rdjF2WTNIQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-11-03T08:00:00+00:00", "published_display": "03 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics Announces $30 Million Investment Agreement with Lynx1 Capital Management", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNM3pNWEJFRzFsY3lsSnpWem55MG04dW1yVmV5QkNVWE9HVGVZWXJyMGhNaHFQZS1mQVRJdDdHQ0FERnRWNlk4dVdVOEdqTkhKaWw4WU42UnBXZkxIU2hETjV2VWJhSl81V3NuT2UyQ1FMMXFBNGhsaTc5SG9QNnZrTy1TYkJTand2alVOME9MWFl6RVhmZDgzTzFZanBWcTVobTBfdHEwOWNXV2dySC12UmV3YVByNDZGdUVBLUNCTXJBb2Fi?oc=5", "source_name": "Quiver Quantitative", "published_at": "2024-12-26T08:00:00+00:00", "published_display": "26 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics (TCRX) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1DMmw3NHlIMEJKalJzaHo4Ty1KZFIzX25xY2xrYVN6V01KaTkyQUtXMnprRW1nelRQcEJhbGVkcjN6MEduU2JkcFRoNDlaNWV1MG13eFRSMnFvQ09JeXZLNGlJZkdNdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T13:37:46+00:00", "published_display": "11 May 2024 13:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for TScan Therapeutics (TCRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9FOWc4UUMtU3dFTWU2ZVljYzJjOC00S3lvZXBsc2xrNU1UZ1ExWFFlWWdjWUxJRzk0Qi1fYXZSTUJRMEZYMUFCVmtlejZocWhLS2ZJRjBLZ09CZ29XUzZvbjBjTy1aNUwwTmpKcGRGXzVqUjdETWdjMw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-08-05T00:57:21+00:00", "published_display": "05 Aug 2022 00:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TCRX: Tscan Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTE51ZWVCa3FSWnB4UkVFcy1GNFNrQk5MZ2NuckhCLUVIZlVoTXF4Ukx6QkZlenItOW1JN0QydkFhTDNLQnZUTk90S0dR?oc=5", "source_name": "Stocktwits", "published_at": "2017-03-22T17:01:28+00:00", "published_display": "22 Mar 2017 17:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates", "summary": "TScan Therapeutics, Inc. (TCRX) announced a Q1 loss, missing revenue estimates. This indicates a challenging start to the fiscal year for the company, with financial performance not meeting analyst expectations.", "url": "https://www.msn.com/en-us/news/other/tscan-therapeutics-inc-tcrx-reports-q1-loss-lags-revenue-estimates/ar-AA22wkC3?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-17T17:39:14", "published_display": "17 Jul 2026 17:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics (TCRX) Q4 2025 earnings summary", "summary": "TScan Therapeutics (TCRX) reported its Q4 2025 earnings, highlighting positive updated data from the ALLOHA Phase 1 heme trial and significant progress in its clinical pipeline, including FDA clearance for new INDs and the launch of a pivotal trial for TSC-101. Financially, the c", "url": "https://quartr.com/events/tscan-therapeutics-tcrx-q4-2025_Fet81OVH", "source_name": "Quartr", "published_at": "2026-07-10T12:10:27", "published_display": "10 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics (TCRX) Status Update Summary", "summary": "TScan Therapeutics (TCRX) provided a status update on its hematologic malignancy program, highlighting positive results from the Phase 1 ALLOHA trial for TSC100 and TSC101, which showed significant relapse reduction and improved event-free survival. The FDA granted RMAT designati", "url": "https://quartr.com/events/tscan-therapeutics-inc-tcrx-status-update_Fet8Top0", "source_name": "Quartr", "published_at": "2026-07-08T11:11:49", "published_display": "08 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics (TCRX) Stock Analysis Report | Financials & Insights", "summary": "This report provides a detailed financial analysis of TScan Therapeutics (TCRX), a clinical-stage biotechnology company focused on developing TCR-T therapies for cancer. It covers general company information, stock performance metrics, Benzinga Edge rankings, financial health ind", "url": "https://es.benzinga.com/quote/TCRX/report", "source_name": "Benzinga Espa\u00f1a", "published_at": "2026-07-06T23:09:46", "published_display": "06 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of TScan Therapeutics, Inc. \u2013 NASDAQ:TCRX", "summary": "This article examines the enterprise value to EBITDA forward for TScan Therapeutics, Inc. (NASDAQ: TCRX). It primarily presents a snapshot of financial data and company information available on TradingView, covering market specifics and financial metrics. The focus is on the valu", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T11:09:18", "published_display": "04 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of TScan Therapeutics, Inc. \u2013 NASDAQ:TCRX", "summary": "This article provides financial information for TScan Therapeutics, Inc. (NASDAQ: TCRX), focusing on its enterprise value to EBIT forward. It indicates a period value and details regarding changes in this metric, accessible through TradingView's platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T19:10:24", "published_display": "01 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics at H.C. Wainwright: phase iii push gains pace", "summary": "TScan Therapeutics presented at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference, announcing the transition of its lead program, TSC-101, into a phase III study. The company highlighted encouraging phase I data showing 100% relapse-free survival in a treated subset ", "url": "https://www.investing.com/news/transcripts/tscan-therapeutics-at-hc-wainwright-phase-iii-push-gains-pace-93CH-4768449", "source_name": "Investing.com", "published_at": "2026-06-30T18:39:50", "published_display": "30 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), TScan Therapeutics (TCRX) and PACS Group Inc (PACS)", "summary": "The article highlights positive analyst sentiments in the Healthcare sector for Definium Therapeutics (DFTX), TScan Therapeutics (TCRX), and PACS Group Inc (PACS). Analysts from JonesTrading, Wedbush, and J.P. Morgan reiterated Buy ratings for the respective companies, citing sig", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PACS/pressreleases/2624972/analysts-offer-insights-on-healthcare-companies-definium-therapeutics-dftx-tscan-therapeutics-tcrx-and-pacs-group-inc-pacs/", "source_name": "The Globe and Mail", "published_at": "2026-06-28T10:11:58", "published_display": "28 Jun 2026 10:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of TScan Therapeutics, Inc. \u2013 NASDAQ:TCRX", "summary": "The article discusses the enterprise value to revenue forward for TScan Therapeutics, Inc. (NASDAQ: TCRX). It appears to be a financial data snippet from TradingView, indicating no specific value or change but rather the financial metric is available. The content primarily shows ", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T14:10:09", "published_display": "26 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of TScan Therapeutics, Inc. \u2013 BOATS:TCRX", "summary": "This article provides the \"Price to sales forward\" financial metric for TScan Therapeutics, Inc. (TCRX) on the Blue Ocean Alternative Trade System (BOATS). It is presented within the context of TradingView's financial data offerings for investors.", "url": "https://www.tradingview.com/symbols/BOATS-TCRX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T12:10:09", "published_display": "26 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics to speak at H.C. Wainwright cell therapy event June 30", "summary": "TScan Therapeutics (Nasdaq:TCRX), a clinical-stage biotechnology company, announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. The company will host a fireside chat at 11:30 a.m. ET, with a live webcast and 90-day replay ", "url": "https://www.stocktitan.net/news/TCRX/t-scan-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-vk5y8c56gnxe.html", "source_name": "Stock Titan", "published_at": "2026-06-24T11:14:33", "published_display": "24 Jun 2026 11:14", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference", "summary": "TScan Therapeutics, a clinical-stage biotechnology company, announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. The company will host a fireside chat on June 30, 2026, at 11:30 a.m. ET, discussing its T cell receptor (TCR)-engineered T c", "url": "https://www.globenewswire.com/news-release/2026/06/24/3316713/0/en/TScan-Therapeutics-to-Participate-in-the-H-C-Wainwright-4th-Annual-Cell-Therapy-Virtual-Conference.html", "source_name": "GlobeNewswire", "published_at": "2026-06-24T11:14:33", "published_display": "24 Jun 2026 11:14", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TCRX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for TScan Therapeutics, Inc. (TCRX) stock, outlining current price, historical performance, and analyst opinions for future price movements. It also includes key financial metrics such as EPS, revenue, market capitalization, and u", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-24T09:11:23", "published_display": "24 Jun 2026 09:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TCRX Reiterated by Needham -- Price Target Maintained at $6.00", "summary": "Needham analyst Gil Blum reiterated a \"Buy\" rating for TScan Therapeutics (TCRX) and maintained a price target of $6.00. The stock is considered undervalued by 48.2% based on GuruFocus's GF Value\u2122 of $1.68 compared to its current price of $0.87. Despite an average GF Score\u2122 of 50", "url": "https://www.gurufocus.com/news/8927545/tcrx-reiterated-by-needham-price-target-maintained-at-600?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-23T17:10:14", "published_display": "23 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TCRX Reiterated by Wedbush -- Price Target Maintained at $5.00", "summary": "Wedbush has reiterated an Outperform rating for TScan Therapeutics (TCRX), maintaining a price target of $5.00. Despite a current market price of $0.87, GuruFocus estimates the stock to be 48.2% undervalued with a GF Value\u2122 of $1.68. While analysts express confidence in the compa", "url": "https://www.gurufocus.com/news/8927568/tcrx-reiterated-by-wedbush-price-target-maintained-at-500?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-23T17:10:14", "published_display": "23 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA\u2122 Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation", "summary": "TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA\u2122 Phase 1 study for TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The study showed 11 of 14 patients achieved complete donor chimerism short", "url": "https://www.sahmcapital.com/news/content/tscan-therapeutics-announces-positive-initial-data-from-cohort-c-of-ongoing-alloha-phase-1-study-evaluating-tsc-101-in-patients-with-heme-malignancies-undergoing-allogeneic-hematopoietic-cell-transplantation-2026-06-22", "source_name": "Sahm", "published_at": "2026-06-23T16:39:37", "published_display": "23 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6", "summary": "Needham has reiterated its Buy rating on TScan Therapeutics (TCRX.US) and maintained its target price at $6. This indicates the firm's continued confidence in the company's financial prospects and valuation.", "url": "https://www.moomoo.com/news/post/71891944/needham-maintains-tscan-therapeutics-tcrxus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-06-23T11:09:03", "published_display": "23 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $7", "summary": "H.C. Wainwright has reiterated its Buy rating for TScan Therapeutics (TCRX.US) and maintained a target price of $7. This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/71891943/hc-wainwright-maintains-tscan-therapeutics-tcrxus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-23T11:09:03", "published_display": "23 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Tscan stock rating on trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOMnNDMHVsaTRZRERMampnWDRaeWw4c2VRR1JIT1BtV3VCRUppWmd1TUx5RlByb2dZSHhiMEg3N0pFaE52bEp4dUJCYmQtR0lOLWNvc0Z0RE9DLXM4TUM4MlBTRTY2ZGU5MUs2MXRGQjJWNVo2YW1pZlR0ZlhpcjRGTzVIZXJXUDVkeUJjSTNvRkh3ai0xZmtCVnV1V1Z2YVYtTXRmQUlFeVFiUVo4dGUxV0lnQWV3MmFM?oc=5", "source_name": "Investing.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics (TCRX) shows strong TSC-101 Phase 1 data, plans pivotal trial", "summary": "TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA\u2122 Phase 1 study for TSC-101, a TCR-T cell therapy for blood cancer patients post-allogeneic stem cell transplant. The data show 11 of 14 patients achieved complete donor chimerism, with 93% exhibiting d", "url": "https://www.stocktitan.net/sec-filings/TCRX/8-k-t-scan-therapeutics-inc-reports-material-event-e2f367ca1aaa.html", "source_name": "Stock Titan", "published_at": "2026-06-23T03:39:40", "published_display": "23 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan reports Phase 1 data for TSC-101 blood cancer trial", "summary": "TScan Therapeutics announced promising initial Phase 1 data for its TSC-101 treatment in blood cancer patients, with 11 out of 14 achieving complete donor chimerism. The company's shares traded down following the news, and TScan expects to enroll the first patient in its pivotal ", "url": "https://grafa.com/en/news/united-states/tscan-therapeutics-tcrx-phase-1-trial-chimerism-data-2026", "source_name": "grafa.com", "published_at": "2026-06-22T13:35:00", "published_display": "22 Jun 2026 13:35", "sentiment": "negative", "sentiment_pct": 39, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tscan-therapeutics-reports-positive-data-123125587.html", "source_name": "MT Newswires", "published_at": "2026-06-22T12:31:25+00:00", "published_display": "22 Jun 2026 12:31", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan reports trial data for blood cancer treatment TSC-101 By Investing.com", "summary": "TScan Therapeutics Inc. (NASDAQ:TCRX) released promising data from Cohort C of its ALLOHA Phase 1 study for TSC-101, a blood cancer treatment. The study showed 11 out of 14 treated patients achieved complete donor chimerism, and the infusions were generally well-tolerated. Despit", "url": "https://ng.investing.com/news/stock-market-news/tscan-reports-trial-data-for-blood-cancer-treatment-tsc101-93CH-2567285", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T11:40:15", "published_display": "22 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Tscan Therapeutics Inc For: 22 June By Investing.com", "summary": "This article announces that Tscan Therapeutics Inc. filed a Form 8K on June 22nd. The brief post from Investing.com includes general market data and related news but offers no specifics about the content of the Form 8K filing itself. The article also touches on various market ind", "url": "https://ca.investing.com/news/stock-market-news/form-8k-tscan-therapeutics-inc-for-22-june-93CH-4700450", "source_name": "Investing.com Canada", "published_at": "2026-06-22T11:40:15", "published_display": "22 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan says 11 of 14 patients hit complete donor chimerism after TSC-101", "summary": "TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA Phase 1 study for TSC-101, reporting that 11 out of 14 patients achieved complete donor chimerism within approximately three weeks of their first infusion. The company also confirmed a ~90% manufacturi", "url": "https://www.stocktitan.net/news/TCRX/t-scan-therapeutics-announces-positive-initial-data-from-cohort-c-of-oj3vilv79red.html", "source_name": "Stock Titan", "published_at": "2026-06-22T10:40:15", "published_display": "22 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of TScan Therapeutics, Inc. \u2013 NASDAQ:TCRX", "summary": "This article provides information about the number of shareholders of TScan Therapeutics, Inc. (NASDAQ: TCRX) through a TradingView interface. It presents data points for \"Period,\" \"Value,\" \"Change,\" and \"Change %\" without specifying the actual shareholder numbers or the periods ", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRX/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-20T05:40:23", "published_display": "20 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics Inc (TCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for TScan Therapeutics Inc (TCRX), focusing on its business segments, regional revenue, and profit contribution. It notes that relevant financial data for FY2025 has not yet been disclosed by the company. The only specific financial detai", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:37", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cellares-tscan-therapeutics-announce-agreement-131900798.html", "source_name": "Business Wire", "published_at": "2026-06-03T13:19:00+00:00", "published_display": "03 Jun 2026 13:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Automated cell therapy push: TScan and Cellares target post-transplant relapse", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQNEZKTFRXYmlpT3ZFdTBEZDJCejZndjJlODlHMjhONDV2RWd2M3UtX19DWGVfX1JBbWhERDM4T19lY3M1SnBWRHFIeGJSV3dialZRR1MxZkhudmt1NjZQQUpwOS1kNEQzRHNhUUN4XzZfQzZ1YllnYWJpMkZjTFJnTW1BemZHZ0E5Mk4wME90bDJzYkotY0c2TXJfcWRoYWtFS3U2aTJYWkRkR1JPV1BNSGhLMnRtRWhYV1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxObkxkdDZ3blhoZmVXYi1VdXJuQUJhN3hNSENQT08wbFQxZmMyUTlFUGFRUlVlS19wYUxISm56Z3R1cThhXzlsUVhsZGxMQU9KM3FGX0VoaTJoUHotc0paUF9DUTk1dG9RU3RoRF8yeWJFMmdhc3lSYVZoRDg1UGZ3UUY5MS1zWXZJOXh2Qzh0QXlkemV6QkFxTFdBQmh1cFRVdWQ4NWJSSQ?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxOa2RUWl9tanUwTmZuQVZMSUxyeTRuOWtMRjJwRkFNSWYxcWlXVnkteloxZERDTVphaXBrcGJuUkl6V0lHRzg0VENsb1RPWmdaenYwY2ZqelpwLU5aYUQ4N1c4Z1Q3eXRSOWtjazh5c25sSHZaRXRSTlZCdHNIV2pEOENrMmJlYll3algxX3lGMFQ0MkJlVFQ5YUFBMkN3enhwdEhwT2JRRlpEMlJhV0VCRW96LWlwczZkVy04b1dZTzhjNkVkcW9vN1NNbjNFSnFjN3ZwYmJFS2RZb1ZFUzc1eW1NYTF6VWhjZDVTYTlBSHJBYXVMM2c?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan lines up Phase 3 blood cancer study as patient data nears", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTXdHVkMzeENObFYzeWtDWFRGZEtGM1JZRVBXNlFkYnVFWjdjTVNVYzdQc3hnd1FqSVJ1dF9OOWp1LW1WRUJOZmRnbm5Jb3VtMllqV3lUTXFHbWNKeFE2MVFILU9tQjZBQk1HNGF2NF9ORVMtY0lfdG5zc2tlRVRqVDVCeG0yT0ZkTzRKcFpOblQ5N1dScDBkbnF0OWVmRWpnZG9ldGhWdkIwSXMzeG9zWDU2VzR6WGU0UVVXTFlrZU0?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tscan-therapeutics-announces-upcoming-presentation-203000315.html", "source_name": "GlobeNewswire", "published_at": "2026-04-27T20:30:00+00:00", "published_display": "27 Apr 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LifeSci Capital Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQR0JzQUljdFQwbTRNSllqeFRhX0tDU1pHVXR5S28xSXFtTmdDNXNnNmZaOWEzWVEyZ3l1OTlTU1VCOGRtTGt0RE03U2hOaDlkQ0JRWFB1eXIzZ2YzYU83TExFZF9WVjhfOVdiTlFmWXdLV0NqbDJ2QU1tUXM1VGZRT0FndDlyclY1YlpHQmdpU21jV3VHVkludUhsMjdab0R0SEZzRVpsZi1rQl9iUEZzVlFsRlFNdGVuN3E4?oc=5", "source_name": "Moomoo", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQQ0hNYlg0bUM5bUlWVDB1NnRPVzFha0l6RTNVeHh1VFJtLTAyRGRUcTRHVEhydFVFRzNNaTVsajZTMENGYmJqcU5fWkQ1aHpCWTd4bC12SmJnQnRMdnIzQnFQX0pkOXcyN1k3eGxDdmNXTWhlQzV4Uk5WMFR1b09VOFlMZUg1ekhRRTI5TW1sZ1hXYjhPUnhTSy1nallxTDVQaVl1YnNJNnB0cG56?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics Announces Positive Phase I Meeting with FDA, Strategic Workforce Reduction, and Focus on Hematologic Malignancies | TCRX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxOcFU1QkRMTnFZWU96aTdvUjNuQWV4Q3hqU081NV9WV1Z4bGI4NDEtMzJLLXltN3RwVEJaWHU1RVdwbzRUM2VCTi1DdXdsSjRXUDM5Q3lha0Z0RVJkSS1UbnhqaVBRR2x5RHh5eTg0cHFlZVQzNW5ETDZXUFdud0xNbW5FaDBmRFc0QkdKblJONHJjLVozcHhBSzRtb1JxZndWZWlqWlZVa0JuS2JTYmUzbjU5YW1ZZlZUbEhTQ3ViZ1l1UTJEVG5WWFhhWmF0N24xd2lOdk5Yb3hFYXdaU3VIaWdMYlltS0JjWHhwMnNVRVJ0c0pEOW5rdjF2WTNIQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-11-03T08:00:00+00:00", "published_display": "03 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics Announces $30 Million Investment Agreement with Lynx1 Capital Management", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNM3pNWEJFRzFsY3lsSnpWem55MG04dW1yVmV5QkNVWE9HVGVZWXJyMGhNaHFQZS1mQVRJdDdHQ0FERnRWNlk4dVdVOEdqTkhKaWw4WU42UnBXZkxIU2hETjV2VWJhSl81V3NuT2UyQ1FMMXFBNGhsaTc5SG9QNnZrTy1TYkJTand2alVOME9MWFl6RVhmZDgzTzFZanBWcTVobTBfdHEwOWNXV2dySC12UmV3YVByNDZGdUVBLUNCTXJBb2Fi?oc=5", "source_name": "Quiver Quantitative", "published_at": "2024-12-26T08:00:00+00:00", "published_display": "26 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TScan Therapeutics (TCRX) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1DMmw3NHlIMEJKalJzaHo4Ty1KZFIzX25xY2xrYVN6V01KaTkyQUtXMnprRW1nelRQcEJhbGVkcjN6MEduU2JkcFRoNDlaNWV1MG13eFRSMnFvQ09JeXZLNGlJZkdNdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T13:37:46+00:00", "published_display": "11 May 2024 13:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for TScan Therapeutics (TCRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9FOWc4UUMtU3dFTWU2ZVljYzJjOC00S3lvZXBsc2xrNU1UZ1ExWFFlWWdjWUxJRzk0Qi1fYXZSTUJRMEZYMUFCVmtlejZocWhLS2ZJRjBLZ09CZ29XUzZvbjBjTy1aNUwwTmpKcGRGXzVqUjdETWdjMw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-08-05T00:57:21+00:00", "published_display": "05 Aug 2022 00:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TCRX: Tscan Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTE51ZWVCa3FSWnB4UkVFcy1GNFNrQk5MZ2NuckhCLUVIZlVoTXF4Ukx6QkZlenItOW1JN0QydkFhTDNLQnZUTk90S0dR?oc=5", "source_name": "Stocktwits", "published_at": "2017-03-22T17:01:28+00:00", "published_display": "22 Mar 2017 17:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 87, "total_relevant": 49, "sentiment_summary": {"positive": 20, "negative": 4, "neutral": 25, "score": 58, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 11.0, "count": 20}, {"event": "earnings", "label": "Earnings", "weight": 8.11, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 4.95, "count": 9}, {"event": "guidance", "label": "Guidance", "weight": 2.0, "count": 3}], "positive_events": 20, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 0.91, "latest_week": "2026-07-17", "one_week_move": -16.1, "four_week_move": -0.6, "twelve_week_move": -27.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.002925, "market_dynamics_buy_signal": false, "relative_strength": -38.076736, "fair_value_gap": -72.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 51.3614, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-16.1% over one week, -0.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "TradingView", "count": 7}, {"label": "Stock Titan", "count": 5}, {"label": "GlobeNewswire", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "Quartr", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "GuruFocus", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 20}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 9}, {"label": "Guidance", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-16.1% over one week, -0.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates"}], "updated_at": "2026-07-22T08:11:10.463552+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}